Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

Online Learning Portal on the Impetus InSite Platform®

A Customer Story

Impetus Digital

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster receives CHMP recommendation for children five to 11 years

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

Sanofi/GSK’s next-generation COVID-19 booster granted EC approval

Two trials compared the immune response induced by VidPrevtyn Beta with approved vaccines

- PMLiVE

Onyx Health Expands with Two New Appointments

Newcastle-based creative agency Onyx Health has continued to grow and expand with the dual appointments of Rosie Thompson as Account Manager and Modupe Ayeni as a Medical Writer

Onyx Health

- PMLiVE

What constitutes a great creative brief?

We asked, you answered, and the results are in… what really does go into a great creative brief?

Page & Page Health

- PMLiVE

ICR calls for further discussions following NICE’s rejection of breast cancer drug

Olaparib has been shown to cut the risk of cancer recurrence and improve survival

- PMLiVE

Novavax’s COVID-19 vaccine receives MHRA approval for use as a booster

Nuvaxovid was shown to increase antibody levels when used as a third booster

- PMLiVE

FDA approves Seagen’s Adcetris combination for paediatric patients with Hodgkin lymphoma

Patients had a 59% reduction in the risk of disease progression or relapse, second cancer or death

- PMLiVE

Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia

The IL-Ra1 inhibitor was found to reduce the risk of disease progression by 64%

Streamlining Cardiac Care with Real Time Monitors

Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, explores his journey from computer engineering to healthcare, innovation in the cardiac monitoring space, the concept of Mobile Cardiac Telemetry (MCT), and...

Impetus Digital

- PMLiVE

MSD’s Vaxneuvance approved by MHRA for prevention of pneumococcal diseases in children

The decision marks the first new vaccine approved by MHRA in a decade for this indication

- PMLiVE

Pfizer/BioNTech’s second bivalent COVID-19 booster approved by MHRA

The adapted vaccine targets the original virus and Omicron BA.4 and BA.5 strains

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links